Detection of NRAS Gene Mutations in Tumor Tissues

The presence of an NRAS gene mutation is a predictor of the lack of response to anti-EGFR antibody therapy in patients with metastatic colorectal cancer. Determination of mutations in the NRAS gene is recommended for patients with unresectable stage III and IV cutaneous melanoma for the possibility of therapy personalization.

Within 12 days. The specified time does not include the day of biomaterial collection